HOWL Logo

Werewolf Therapeutics, Inc. (HOWL) 

NASDAQ
Market Cap
$71.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
555 of 775
Rank in Industry
299 of 432

Largest Insider Buys in Sector

HOWL Stock Price History Chart

HOWL Stock Performance

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a …

Insider Activity of Werewolf Therapeutics, Inc.

Over the last 12 months, insiders at Werewolf Therapeutics, Inc. have bought $0 and sold $0 worth of Werewolf Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Werewolf Therapeutics, Inc. have bought $75.84M and sold $40,242 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,853,000 shares for transaction amount of $4.1M was made by RA CAPITAL MANAGEMENT, L.P. (director) on 2023‑01‑06.

List of Insider Buy and Sell Transactions, Werewolf Therapeutics, Inc.

2023-01-06Purchasedirector
1.85M
5.9218%
$2.21$4.1M+17.33%
2021-12-15SaleChief Operating Officer
3,000
0.0157%
$13.41$40,242-65.47%
2021-06-16Purchase
9,285
0.0512%
$13.37$124,140+0.29%
2021-06-15Purchase
7,958
0.0452%
$12.95$103,056+6.61%
2021-06-14Purchase
306,055
1.727%
$12.75$3.9M+7.62%
2021-05-04Purchase10 percent owner
245,000
1.3777%
$16.00$3.92M-12.48%
2021-05-04Purchase
150,799
0.848%
$16.00$2.41M-12.48%
2021-05-04Purchase
1.72M
9.6439%
$16.00$27.44M-12.48%
2021-05-04Purchase10 percent owner
125,759
0.7072%
$16.00$2.01M-12.48%
2021-05-04Purchase10 percent owner
800,000
4.4986%
$16.00$12.8M-12.48%
2021-05-04Purchase10 percent owner
312,500
1.7573%
$16.00$5M-12.48%
2021-05-04Purchase
312,500
1.7573%
$16.00$5M-12.48%
2021-05-04Purchase
400,000
2.2493%
$16.00$6.4M-12.48%
2021-05-04Purchase10 percent owner
400,000
2.2493%
$16.00$6.4M-12.48%
2021-05-04Purchase10 percent owner
250,000
1.4058%
$16.00$4M-12.48%
2021-05-04Purchase10 percent owner
475,000
2.671%
$16.00$7.6M-12.48%
2020-12-23Purchase
15.88M
$0$0
2020-12-23Purchase
7.6M
$0.46$3.5M
2020-12-23Purchase
7.12M
$8.00$56.97M

Insider Historical Profitability

<0.0001%
GADICKE ANSBERT10 percent owner
6672183
14.9724%
$1.6110<0.0001%
RA CAPITAL MANAGEMENT, L.P.director
5701056
12.7932%
$1.6150+3.88%
EVNIN LUKE
4284172
9.6137%
$1.6120<0.0001%
MPM BioVentures 2014, L.P.10 percent owner
3187998
7.1539%
$1.6110<0.0001%
Flynn James E10 percent owner
2552787
5.7285%
$1.6110<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$39.82M14.146.14M0%+$00.04
MPM Asset Management LLC$27.76M9.864.28M0%+$011.32
PFM Health Sciences$19.48M6.923.01M-13.3%-$2.99M0.54
Adage Capital Partners Gp L L C$19.44M6.913M-1.11%-$218,123.280.04
Bioimpact Capital Llc$15.47M5.52.39M0%+$02.51
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.